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Background: The 6-Minute Walk Test (6MWT) is representative of daily-life activities and reflects the functional
capacity of patients. The change of oxygen uptake (VO2) in the initial phase of low-intensity exercise (VO2 kinetics)
can be used to assess submaximal exercise performance of patients.
The objective of the following study was to analyse VO2 kinetics in patients with different pulmonary and
cardiovascular diseases. In addition, we investigated the extent to which VO2 kinetics at the onset of the 6MWT
were associated with exercise capacity, morbidity and mortality.
Methods: VO2 kinetics of 204 patients and 16 healthy controls were obtained using mobile telemetric
cardiopulmonary monitoring during a 6MWT. A new mean response time (MRT) index (wMRT) was developed to
quantify VO2 kinetics by correcting MRT for work rate. The differences in wMRT between disease categories as
well as the association between wMRT and patients’ exercise capacity and outcome - time to hospitalization/
death- were tested.
Results: The assessment of a robust wMRT was feasible in 86% (244/284) patients. wMRT was increased in patients
compared to healthy controls (p <0.001). wMRT was largest in patients with pulmonary arterial hypertension (PAH).
There were significant associations between wMRT and exercise capacity in all patients. High wMRT was found to
be associated with a high rate of death and re-hospitalization in patients with CHF (p = 0.024). In patients with
pulmonary diseases and pulmonary hypertension wMRT was not associated with outcome (p = 0.952).
Conclusions: Submaximal exercise performance of patients is reduced. O2 kinetics at the onset of exercise are
associated with exercise capacity in all patients. wMRT was found to be an important prognostic factor in patients
with congestive heart failure (CHF), but not with pulmonary diseases.
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Cardiopulmonary exercise testingBackground
Cardiopulmonary exercise testing (CPET) has been clas-
sically performed on a cycle-ergometer or motorised
treadmill using a rapid ramped incremental protocol to
the limit of tolerance [1]. Since most activities of daily
living are performed in a non-incremental fashion and at* Correspondence: martin.brutsche@kssg.ch
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unless otherwise stated.submaximal level of exertion, the 6-Minute Walk Test
(6MWT) may be more representative of daily-life activ-
ities and may reflect the functional capacity of patients
more accurately [2]. In addition, because most activities
of daily living require repetitive submaximal effort, it
may be postulated that analysing the cardiopulmonary
responses during a transition from rest to submaximal
intensity work may provide important information.
Therefore, there is a growing interest in submaximal ex-
ercise parameters capable of reflecting the functional
capacity of patients.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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work exercise (VO2 on-kinetics) is classically subdivided
into three functionally distinct phases [3,4]. A rapid first
phase characterized by a short time delay of approximately
20 seconds reflects an increase in pulmonary blood flow.
After the first phase, O2 uptake gradually increases in an
approximately mono-exponential fashion (phase 2) until a
steady state level (VO2SS) (phase 3) is attained. Phase 2 re-
flects the ability of the cardiopulmonary system to deliver
oxygen and the amount of oxygen that is utilized by skel-
etal muscles. At the onset of exercise there is a delay in
skeletal muscle mitochondrial ATP production due to a
limited oxygen supply (oxygen deficit). Until the steady
state is attained, anaerobic glycolysis compensates for this
short-term oxygen deficit [5,6].
VO2 on-kinetics can be characterized by the time
(mean response time: MRT) required for VO2 to achieve
63% of the VO2SS in response to physical stress [7,8].
MRT is usually calculated in a CPET setting using a con-
stant work rate protocol [8,9]. As the work rate during
the 6MWT is mostly determined by the patients’ indi-
vidual effort, MRT has to be calculated differently. In
this study, a new MRT index (wMRT) is proposed to
quantify VO2 kinetics at the onset of exercise by correct-
ing MRT for work rate during the first phase of the
6MWT.
It has been demonstrated that patients with chronic
pulmonary or cardiac disorders exhibit slower VO2 on-
kinetics [10,11] when compared to healthy age-matched
controls.
More knowledge of the physiological determinants of
O2 uptake kinetics at the onset of exercise may lead to a
better understanding of the pathophysiological mecha-
nisms causing functional impairments in patients. The
importance of assessing VO2 kinetics in the initial phase
of low-intensity exercise may be underlined by that fact
that peak VO2 during a maximal exercise test is influ-
enced by conditions other than the underlying disease,
the patient’s motivation and the criteria used to termin-
ate the test [12]. In addition, it has been demonstrated
in several chronic diseases that VO2 on-kinetics have a
higher prognostic value than peak VO2 [13].
No data exist about the clinical utility of this refined
method to quantify functional capacity of patients.
Therefore, the main purpose of the present study was to
analyse VO2 kinetics at the onset of exercise in patients
with different pulmonary and cardiovascular diseases
using mobile telemetric cardiopulmonary monitoring
(MOB). Given the vast pathophysiological heterogeneity
of these diseases it may be reasonable to presume that
different diseases may have different VO2 kinetics. Sec-
ondarily, we investigated the extent to which VO2 kinet-
ics are associated with exercise capacity (VO2SS and
6-Minute Walking Distance, 6MWD). The third aim ofthe present study was to investigate if VO2 kinetics are as-
sociated with morbidity and mortality in these patients.
Methods
Study design
Patients referred to the Pulmonary Division of the Uni-
versity Hospital Basel, Switzerland between August 2003
and June 2007 were considered for participation in the
study (Figure 1). Healthy volunteers were recruited from
among the hospital staff and college students. Exclusion
criteria were as follows: need for oxygen supply or rest-
ing transcutaneous oxygen saturation (SpO2) of <85%
while breathing room air, inability to walk, any acute
coronary event during the previous month and condi-
tions precluding the use of a face mask (e.g. anatomic
anomaly, claustrophobia or panic disorder). The follow-
up was performed by interviewing the referring phys-
ician and/or by chart review.
All patients gave informed consent. Our local institu-
tional review board (Ethikkommission beider Basel (EKBB))
approved the study. Parts of the study population data had
also been used in another study evaluating the feasibility
and safety and clinical usefulness of a MOB-enhanced
6MWT [14].
Six-minute walk test
The 6MWT was performed according to the guidelines
published by the American Thoracic Society (ATS) [2]
with a standardized encouragement in a 30 m corridor.
All tests were conducted by the same experienced tech-
nician. Before starting the 6MWT, patients rested seated
for three to five minutes until stable VO2 values were re-
corded (VO2rest). Spirometry was performed prior to
the test. The 6MWT was followed by a recovery phase,
where the patient rested on a chair. Total walking dis-
tance, Borg's dyspnoea score and the subjective limiting
factor were recorded.
Six-minute walk test with MOB device
We used the Oxycon Mobile® (Viasys Healthcare, USA)
portable, wireless cardiopulmonary exercise testing de-
vice to measure breath-by-breath oxygen exchange kin-
etics. Pulse rate was determined using an ECG-triggered
belt (Polar® Electro OY T-61). SpO2 was measured using
a finger clip. VO2 and carbon dioxide output (VCO2),
tidal volumes and breathing frequency were assessed
using a facemask (dead space <70 ml) with a flow sensor
and a gas analyser. The patient carried data storage and
transfer units by using a dedicated harness. Wireless
transfer of breath-by-breath data to a laptop computer
allowed real-time monitoring. The additional weight
(950 g) of the equipment has no effect on walking dis-
tance [14]. The exact 6MWT-MOB procedure has been




220 subjects completed the study
Lost during follow-up (3),






Inaccurate MRT estimation (38) 
- 22 without VO2 plateau
- 16 with marked VO2 variability
Figure 1 Study exclusions due to technical issues or loss of follow-up. Nine (3%) tests were excluded due to significant patient-related or
technical flaws. In thirty-eight (15%) tests it was not possible to fit an acceptable oxygen uptake kinetics curve. Two hundred and twenty tests
(82%) were included in the final analysis.
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were applied [1]: the effort was considered to be max-
imal if either one or more of the following criteria were
fulfilled: (1) maximal heart rate >90% predicted, (2)
VO2peak >84% of the predicted maximum, and (3) ven-
tilatory reserve <11 liters or <15%. Ventilatory reserve,
VO2max predicted and maximal predicted heart rate
were calculated using standard equations [15,16]. Spir-
ometry was interpreted according to the ATS/ERS
guidelines [17].
Curve fitting of oxygen uptake
Original breath-by-breath data were imported from the
MOB device. Raw data were pre-processed by averaging
the breath-by-breath measurements over consecutive pe-
riods of 20 seconds (Figure 2, panel A and B). Curves
were modelled using asymptotic regression models de-
scribing the oxygen uptake during the 6MWT.
f tð Þ ¼ y1 þ y2−y1ð Þ 1−e−t=τ
 
with y1 the lower limit at t = 0, y2 the upper limit, and the
parameter τ >0 determining the steepness of the increase as
t elapses. In physiological terms, this translates into:




with VO2rest the oxygen uptake at rest, and VO2ss the
oxygen uptake at steady state during exercise.
Notice that the phase I classically characterized by a
short time delay was not modelled in the current study.This time delay was undistinguishable from the second
exponential phase as often happening in vivo [18]. A
gain of stability was obtained by not using an over-
parameterized model, which over compensated the po-
tential risk of slight systematic over estimation of τ.
The oxygen deficit (O2def ) is defined as the area be-
tween an instantaneous increase of oxygen to the max-
imum upper limit and the observed asymptotic rise of
oxygen (Figure 2, panel C) [19]. Since no time delay is
taken into account, the mean response time (MRT) cor-
responds to the time constant (τ) of the exponential
function describing the rate of oxygen increase [10]. It
represents to the time needed for a 63% increase in oxy-
gen uptake and can also be defined as follows:
MRT ¼ VO2def
VO2SS−VO2rest
Models were fitted on VO2 kinetics using nonlinear re-
gression with the standard Gauss-Newton optimization
algorithm and assuming error terms which are normally
distributed, mutually independent, centred around 0
and of unknown variance. Each individual curve was
analysed graphically and the goodness-of-fit was first
assessed visually and with the help of the Neill’s lack-
of-fit test [20].
Mean response time reparameterization
In this study, a new MRT index (wMRT) was developed
to quantify VO2 kinetics at the onset of exercise by cor-
recting MRT for work rate during the first phase of the
6MWT. The difference between O2 uptake at rest and
Figure 2 Pre-processing of oxygen uptake during 6MWT and curve fitting. Panel A shows the raw breath-by-breath data. Panel B displays
the data after averaging over successive periods of 18 seconds. Panel C depicts the curve fitting (red line) during the 6-minute walk test (6MWT),
together with the parameter estimates including the lower limit (y1), the upper limit (y2), and the oxygen deficit (O2def), from which the mean
response time is derived.
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work rate during the first phase of the 6MWT. MRT
was then reparameterized as follows:
wMRT ¼ MRT
VO2SS−VO2rest
MRT reparameterization using other variables such as
walking distance (WD) was not possible, probably be-
cause of the fact that WD reflects total exercise capacity
rather than the initial phase of a submaximal exercise
test and is also influenced by muscular or skeletal func-
tion as well as motivational level.
Statistical data analysis
Descriptive data for continuous variables are expressed as
mean, standard deviation and percentages for frequencies.
Variables were tested for parametric distribution by apply-
ing the Shapiro-Wilk Test (null hypothesis rejection set
at p < 0.25). Univariate linear regression was performed
to evaluate possible associations between wMRT and
measures reflecting exercise capacity (VO2SS, 6MWD). A
p-value of <0.05 was considered to indicate statistical sig-
nificance. Differences between continuous variables were
tested using linear models (ANOVA F-test). Time-to-event
data was modelled using Kaplan-Meier estimators, and hy-
pothesis testing was performed using Cox-proportional
hazards regression (Wald test). All the analyses were done
using the R statistical software [21], including the extension
package drc for curve fitting [22] and nlstools for the diag-
noses of the quality of fit in nonlinear regression [23].
Results
Fit of oxygen kinetics and patient characteristics
Two hundred and eighty two individuals were examined.
Nine patients had to be excluded for reasons of technicalfailure, insufficient cooperation or incomplete data. Fif-
teen patients were excluded due to loss of follow-up,
lung transplantation and diagnosis of malignancy. The
quality of fit was first assessed visually by two independ-
ent investigators in order to detect fits showing obvious
lack-of-fit. In thirty-eight patients from all categories
except controls, curve fitting did not succeed, leading
to exclusion from the analysis. Two distinct patterns
of response to exercise were noticed in this group: in
twenty-two patients, oxygen uptake did not show a plat-
eau and in sixteen patients, VO2 showed a marked vari-
ability after reaching a plateau. Variable walking speed
and pauses during the 6MWT are the most likely expla-
nations for this observation. The exclusion process is
depicted in Figure 1.
The goodness-of-fit of each of the remaining 220
curves was further assessed using Neill’s lack-of-fit test
for nonlinear regression. This test showed no evidence
of lack-of-fit for all curves but four, where the Neill’s test
provided significant results (adjusted p-values <0.05).
These four curves were nevertheless kept in the final
analysis as their lack-of-fit was not considered major,
and was not significantly impacting the estimate of the
model parameters.
Two hundred and four patients and sixteen healthy con-
trols were included in the final analysis. Patient character-
istics are reported in Table 1. One hundred and twenty
eight patients (58%) reached criteria for maximal effort
according to ATS guidelines [1]. In the current study
the mean RER was 0.86 (0.14) suggesting that only a few
patients reached an anaerobic threshold. Patients were
categorized according to their underlying diseases: thirty
nine patients suffered from restrictive lung disease, eighty-
four from COPD, fifty-four from pulmonary arterial hyper-
tension (PAH) and twenty-seven from congestive heart
failure (CHF).
Table 1 Characteristics of participants
Healthy COPD Restrictive PAH CHF
n 16 84 39 54 27
Sex (females) 8 40 21 36 12
Age (years) 37 ± 12 62 ± 14 63 ± 11 61 ± 14 70 ± 9
BMI (kg/m2) 24 ± 4 26 ± 6 30 ± 7 28 ± 6 31 ± 8
FEV1(l/s) 3.9 ± 0.9 1.3 ± 0.5 1.8 ± 0.6 1.9 ± 0.7 (n = 53) 2.4 ± 0.8
FVC (l) 5.0 ± 1.3 (n = 15) 2.6 ± 0.8 2.3 ± 0.8 2.8 ± 1.0 (n = 53) 3.3 ± 1.2
FEV1/FVC 0.8 ± 0.1 (n = 15) 0.5 ± 0.1 (n = 82) 0.8 ± 0.1 0.7 ± 0.2 (n = 53) 0.7 ± 0.1
VO2SS (ml/min) 2376 ± 630 1031 ± 264 1144 ± 299 961 ± 263 1184 ± 342
VO2MAX (ml/min) 2377 ± 630 1012 ± 272 1156 ± 289 945 ± 261 1191 ± 331
VO2MAX (% predicted) 96 ± 15 60 ± 17 66 ± 19 58 ± 18 66 ± 14
HRmax (%predicted) 86 ± 10 69 ± 13 71 ± 12 73 ± 16 70 ± 13
Walking distance (m) 720 ± 83 357 ± 110 381 ± 111 339 ± 120 341 ± 91
Borg 4.1 ± 2.4 4.8 ± 2.4 (n = 80) 4.7 ± 2.1 4.9 ± 2.6 4.5 ± 2.5
Follow-up time (months) 38 ± 6 16 ± 13 21 ± 16 16 ± 14 14 ± 12
Death (n) 0 4 3 10 0
Hospitalizations during follow-up 0 34 17 27 14
MRT (min) 1.13 ± 0.28 1.06 ± 0.28 1.08 ± 0.32 1.07 ± 0.30 0.92 ± 0.34
wMRT (min2/ml) 0.66 × 10−3 ± 0.13 2.18 × 10−3 ± 1.68 1.72 × 10−3 ± 0.81 2.59 × 10−3 ± 1.18 1.62 × 10−3 ± 0.55
Data are presented as mean (SD). BMI: body mass index; FEV1: forced expiratory volume in one second; FVC; forced expiratory vital capacity: FEV1/ FVC ratio:
forced expiratory volume in 1 sec (FEV1) expressed as % of FVC; VO2SS = oxygen uptake at steady state; VO2MAX =maximum oxygen uptake; HRmax: maximum
heart rate: MRT: mean response time; wMRT: mean response time corrected for work rate.
The participants are grouped into 5 categories: healthy controls (Healthy); restrictive lung disease (Restrictive); chronic obstructive pulmonary disease (COPD);
pulmonary arterial hypertension (PAH); congestive heart failure (CHF).
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Exercise capacity as assessed by both 6MWD and VO2SS
of the patients was significantly reduced compared to that
of the healthy controls (Table 1; p <0.001). Exercise cap-
acity did not differ between the different patient categor-
ies. Figure 3 shows the box plot distributions of wMRT ofFigure 3 Mean response time in the various participants’ categories.
following categories: healthy controls (Healthy); restrictive lung disease (Res
arterial hypertension (PAH); congestive heart failure (CHF). The reparameter
healthy controls (p <0.001), the latter showing low wMRT values. Patients s
(p = 0.010), restrictive lung disease (p <0.001) and with CHF (p <0.001).the patients with restrictive lung disease, COPD, PAH
as well as the patients with CHF. The reparameterized
wMRT showed significant differences between patients
and healthy controls (p <0.001), the latter showing low
wMRT values. Patients with PAH had significantly higher
wMRT values as compared with patients with COPDThe figure shows the box plot distributions of wMRT within the
trictive); chronic obstructive pulmonary disease (COPD); pulmonary
ized wMRT showed significant differences between patients and
uffering from PAH have higher wMRT values than patients with COPD
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and patients with CHF (p <0.001).
Association between oxygen kinetics at exercise onset
and exercise capacity
The results of univariate regression analysis are demon-
strated in Table 2. The reparameterized wMRT showed a
significant association with exercise capacity (VO2SS) in all
patients (Figure 4A). Figure 4B demonstrates the associ-
ation between wMRT and VO2SS in the different disease
categories. The reparameterized wMRT showed highly
significant associations with VO2SS in patients with COPD
(p <0.001), restrictive lung disease (p <0.001) and patients
with PAH (p <0.001) (Figure 4B). In all patient categories
wMRT was significantly associated with 6MWD.
Morbidity and mortality
The follow-up was 17 ± 14 months. Seventeen patients
(8%) died and 91 (45%) had to be hospitalized during
follow-up. Ninety-five patients (47%) reached the com-
bined endpoint of either death or hospitalization. The
red dots in Figure 4B show the patients who suffered an
event (death or re-hospitalization) during the follow-up
period. Figure 5 gives the results of the Kaplan-Meier
analysis of the patients with chronic lung disease includ-
ing pulmonary hypertension and chronic heart failure
dichotomized according to the median wMRT (non-
cardiac patients: 1.85×10−3, cardiac patients: 1.59×10−3)
into “Low wMRT” and “High wMRT”. No statistical
difference was found in patients with chronic lung
disease including pulmonary hypertension. In patients
with chronic heart disease, a low wMRT was associated
with a good outcome, i.e. lower rate death and re-
hospitalization (p = 0.024). In patients with pulmonary
diseases and pulmonary hypertension wMRT was not as-
sociated with outcome (p = 0.952).
Discussion
The main purpose of the present study was to analyse
VO2 kinetics during the 6MWT in a relatively large
population of patients with different pulmonary and car-
diovascular diseases using mobile telemetric cardiopul-
monary monitoring (MOB). A new MRT index (wMRT)Table 2 Association between wMRT and exercise capacity
VO2SS (ml/min)
β p R2 β
COPD −399.8 <0.001 0.411 199.7
Restrictive −479.3 <0.001 0.443 503.5
PAH −425.9 <0.001 0.608 236.5
CHF −276.7 0.074 0.122 528.7
Univariate regression is expressed as β and R2. VO2SS = oxygen uptake; 6MWD = 6-m
corrected for work rate.was developed to quantify VO2 kinetics by correcting MRT
for work rate. The relevance of this new parameterization
was further confirmed by the reproducibility of the prior
results from Schalcher and colleagues [9]. wMRT was
lower in all patients’ categories compared to healthy con-
trols. Patients with PAH had a significant higher wMRT
value compared to the other patients. We found signifi-
cant associations between wMRT and exercise capacity in
all patients. Furthermore, wMRT was found to be a signifi-
cant prognostic factor in patients with CHF, but not in pa-
tients with lung diseases and PAH.
6MWT is easy to administer, well tolerated, and more
reflective of activities of daily living than incremental
maximal cardiopulmonary exercise testing (CPET) per-
formed on a cycle-ergometer. In addition, because some
individuals may not tolerate individualized maximal in-
cremental exercise testing, analysing VO2 kinetics during
6MWT may be a useful alternative to CPET.
There has been controversy about the physiologic re-
sponses to the 6MWT in patients and described as both
maximal [24,25] and submaximal [26] sustainable exer-
cise. Interestingly, in this study we found that 128
patients (58%) reached criteria for maximal effort ac-
cording to the ATS guidelines [1]. Detailed information
on factors limiting exercise has been presented in previ-
ously published work [14]. Furthermore, although exer-
cise capacity was clearly diminished, no difference was
found between the exercise capacity of the patients with
different pulmonary and cardiovascular diseases. Despite
the vast pathophysiological heterogeneity of these dis-
eases we found that end-exercise oxygen uptake during
the 6MWT was not different between patients groups.
On the other hand, we found that the O2 kinetics at the
onset of exercise were clearly different between groups.
The results of the present study may, therefore, lead to a
better understanding of the pathophysiological mecha-
nisms causing functional impairments in these patients.
The oxygen uptake at the onset of exercise is the prod-
uct of cardiac output (CO) and the arterial-venous
oxygen difference. The relative contribution of Q deter-
minants (i.e., heart rate (HR) and stroke volume (SV)) to
oxygen uptake is essential in reducing the O2 deficit and
corresponding metabolic demand during exercise. The6MWD (m) MRT (min)
p R2 β p R2
0.007 0.086 0.40 <0.001 0.31
<0.001 0.299 0.35 0.005 0.19
<0.001 0.208 0.20 0.032 0.09
0.004 0.282 0.31 0.039 0.16
inute walk distance; MRT: mean response time; wMRT: mean response time
AB
Figure 4 Scatterplot showing the relationship between wMRT and VO2ss. A Scatterplot showing the relationship between wMRT and VO2SS
in healthy controls (green dots) and in patients (blue dots). B Scatterplot showing the relationship between wMRT and VO2SS in patients with
chronic obstructive pulmonary disease (COPD), restrictive lung disease (Restrictive), pulmonary arterial hypertension (PAH) and congestive heart
failure (CHF). The red dots in the scatter plot show the patients who suffered an event (death or re-hospitalization) during the follow-up period.
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dominantly depends on the increase in SV and due to an
increase in heart rate.
The delay in O2 kinetics at the onset of exercise
(wMRT) was largest in patients with PAH. A significant
difference in wMRT was found between patients with
PAH and the rest of the patients. As patients with
PAH exhibit impairment in the distensibility and vaso-
dilatory capacity and reduction in the size of thepulmonary vascular bed, the capacity for SV to augment
CO is limited [27-30]. In addition, exercise stresses
the pulmonary circulation even more causing an abnor-
mal increase in pulmonary artery pressure (PAP) during
exercise (exercise-induced pulmonary hypertension)
[31-33]. As exercise even further increases PAP during
the 6MWT in PAH, this could explain the significant
difference in wMRT found between patients with CHF
and PAH in the current study.






















































Figure 5 Reparameterized mean response time and time to death and/or hospitalization during follow-up. The Kaplan-Meier curves
depict the time to death and/or hospitalization in non-cardiac (left panel) and cardiac (right panel) patients, as a function of the reparameterized
mean response time (wMRT) dichotomized (based on the median wMRT: non- cardiac patients: 1.85V10−3, cardiac patients: 1.59×10−3) into low
vs. high wMRT categories.
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kinetics at the onset of exercise was associated with both
6MWD and VO2SS. Although reduction in exercise
capacity in patients with COPD is predominantly related
to the combination of increased ventilatory requirements
(mainly secondary to increased ventilation/perfusion
mismatching) and acute derangements in dynamic venti-
latory mechanics, the role of diminished stroke volume
on exercise capacity may be underlined by the results of
the present study. Borghi-Silva and colleagues [10] have
recently demonstrated, that VO2 on-kinetics were asso-
ciated with disease severity in patients with COPD.
Hyperinflation may play an important role regarding
heart size and heart dysfunction in patients with COPD.
Watz and colleagues [11] found that patients with
COPD have an impaired left ventricular diastolic filling
and an impaired global right ventricular function and
that impaired left ventricular diastolic filling was inde-
pendently associated with a reduced exercise tolerance.
These results may eventually aid in the development of
therapeutic approaches to improve the exercise capacity
in patients with COPD.
The delay in O2 kinetics at the onset of exercise in pa-
tients with heart failure was associated with 6MWD too.
In patients with heart failure, delayed O2 on-kinetics may
primarily be reduced due to systolic and/ or diastolic left
ventricular dysfunction [34,35]. Controversially, other re-
searchers found that impaired chronotropic and vasodila-
tor reserves limit exercise capacity in patients with heart
failure [36,37].
Besides the changes in SV, a reduced arterial-venous
oxygen difference may also play a significant role in the
oxygen uptake at the onset of exercise. The latter is
dependent on systemic blood flow, the amount of oxygenextraction possible from the systemic capillary blood, and
the degree of arterial hypoxemia. Studies evaluating the
physiological determinants of O2 uptake kinetics showed
that abnormal oxidative metabolism at the skeletal muscle
level may also contribute to delayed oxygen-uptake kinet-
ics and to the decreased exercise capacity in patients with
several chronic diseases [35,38].
Meyers and colleagues investigated if exercise capacity
is predictor of mortality in a total of 6213 healthy sub-
jects and those with cardiovascular disease. In both
groups, the peak exercise capacity achieved was a stron-
ger predictor of an increased risk of death than other
established risk factors for cardiovascular disease such as
hypertension, smoking, and diabetes [39].
In terms of prognosis, our results are in line with the
previous findings showing that high MRT values are as-
sociated with a bad prognosis in CHF patients [9]. On
the other hand, wMRT was not associated with a bad
prognosis for patients with lung disease or PAH.
Limiting factors of our study include the fact that
MRT could not be calculated in all patients. In about
17% of cases the curve fit failed. Some of these patients
were not able to perform the 6MWT with a constant
walking speed or without interruptions. This fact may be
the reason for the marked variability in VO2 in 16 pa-
tients in whom curve fitting failed. Those patients whose
VO2 did not reach a plateau probably increased their
walking speed during the 6MWT thus also increasing
work rate. In addition they may have been exercising
above their anaerobic threshold which permits an up-
ward shift in VO2 and an increased demand on central
oxygen transport mediated by increased peripheral me-
tabolism. In the current study only 5 of 204 patients
(2.2%) reached the level of RER ≥1.10 suggesting that
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addition, the RER maximal-exercise RER ≥1.10 is com-
monly used as a criterion to determine whether a “true”
VO2max has been attained during maximal-effort exercise
testing. It should however be stressed, that the use of
RER ≥1.10 as a criterion for a valid or “true” VO2max in
patients with pulmonary diseases has been challenged.
Peak exercise performance despite low RER is often seen
in patients with a pulmonary limitation to exercise [40].
We did not match age and gender between cases and
controls because the purpose of the present study was not
to demonstrate exercise intolerance in patients. The current
study was in essence “observational”. For this purpose, a
cross-sectional design was chosen, using only one single
transition per participant. It should be stressed that this may
have jeopardized the accuracy and precision of our data.
Conclusion
In conclusion, no difference was found between the ex-
ercise capacity of the patients with different pulmonary
and cardiovascular diseases. The delay in O2 kinetics at
the onset of exercise (wMRT) was largest in patients
with PAH. Furthermore, we found significant associa-
tions between wMRT and exercise capacity in patients
with lung diseases, heart failure and PAH. wMRT was
found to be a significant prognostic factor in patients
with CHF, but not with pulmonary diseases. The results
of the present study may lead to a better understanding
of the pathophysiological mechanisms causing functional
impairments in these patients. We, therefore, recom-
mend assessing wMRT in future studies investigating ex-
ercise capacity, morbidity and mortality in patients with
pulmonary diseases and heart failure.
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